Michael R. Green, Ph.D.
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice Chair for Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Griffith University, South East Queensland, AUS, PHD, Molecular Genetics |
| 2006 | Victoria University of Wellington, Wellington, NZL, BS, Cell and Molecular Biology |
| 2005 | Victoria University of Wellington, Wellington, NZL, BS, Human Genetics/Molecular Pathology |
Postgraduate Training
| 2011-2013 | Research Fellowship, Medical Oncology, Stanford University, Stanford, CA |
| 2009-2011 | Research Fellowship, Medical Oncology, Dana-Farber, Boston, MA |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, 2014 - 2017
Instructor, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 2013 - 2014
Other Professional Positions
Laboratory Director, Lymphoma Tissue Bank, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Honors & Awards
| 2023 | Janet Rowley Award, Jonas Center for Cellular Therapy, University of Chicago |
| 2023 | Faculty Scholar, MD Anderson Cancer Center |
| 2022 | Chair, Scientific Committee on Lymphoid Neoplasia, American Society of Hematology |
| 2020 | Scholar Award, Leukemia and Lymphoma Society |
| 2020 | President’s Recognition of Faculty Excellence, MD Anderson Cancer Center |
| 2020 | Sabin Family Foundation Fellow Award, MD Anderson Cancer Center |
| 2020 | 2020 Emil Frei III Award for Excellence in Translational Research, Division of Cancer Medicine. MD Anderson Cancer Center |
| 2017 | Rising STARS Award, University of Texas System |
| 2012 | Special Fellow Award, Leukemia and Lymphoma Society |
| 2012 | Millennium Pharmaceuticals Fellowship, Lymphoma Research Foundation (Declined) |
| 2010 | Fellow Award, Leukemia and Lymphoma Society (Declined) |
| 2006 | Presenter Award, International Congress of Human Genetics |
| 2006 | Anthony Herbert Postgraduate Research Scholarship, Griffith University |
| 2006 | Griffith University Postgraduate Research Scholarship, Griffith University |
Professional Memberships
Grant & Contract Support
| Date: | 2022 - 2027 |
| Title: | BAF complex deregulation in lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | 1-R01-CA266279 |
| Date: | 2022 - 2027 |
| Title: | Identifying/targeting mechanisms of lymphomagenesis driven by CREBBP inactivation |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | 2R01CA201380-06A1 |
| Date: | 2022 - 2026 |
| Title: | Targeting SMARCA4 mutations in pediatric Burkitt Lymphoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| ID: | RP200208 |
| Date: | 2021 - 2023 |
| Title: | Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Date: | 2021 - 2026 |
| Title: | Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Date: | 2020 - 2025 |
| Title: | Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
Selected Publications
Peer-Reviewed Articles
- Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell 42(4):605-622.e11, 2024. e-Pub 2024. PMID: 38458188.
- Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B-cell fate and lymphomagenesis. Cancer Cell 42(4):583-604.e11, 2024. e-Pub 2024. PMID: 38458187.
- Li X, Henderson J, Gordon M, Sheikh I, Nastoupil L, Westin J, Flowers C, Ahmed S, Wang L, Neelapu S, Strati P, Deng Q, Green M.. A single cell atlas of CD19 chimeric antigen receptor T-cells. Cancer Cell 41(11):1835-1837, 2023.
- Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Balada G, Deaton L. Cain T, Yang H, Ravanmehr V, Fayad L, Iyer S, Nastoupil L, Hagemeister F, Cuentas E, Saini N, Takahashi K, Fowler N, Westin J, Steiner R, Nair R, Flowers C, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu S, Green M.. Prolonged cytopenia following CD19 CAR T-cell therapy is associated with bone marrow infiltration of clonally-expanded IFNγ-expressing CD8 T-cells. Cell Reports Medicine 4(8):101158, 2023.
- Gourisankar S, Krokhotin A, Ji W, Liu X, Chang C, Kim S, Li Z, Wenderski W, Simanauskaite J, Yang H, Vogel H, Zhang T, Green M, Gray N, Crabtree G.. Rewiring cancer drivers to activate apoptosis. Nature 620(7973):417-425, 2023.
- Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv. e-Pub 2023. PMID: 37389847.
- Chu Y, Li Y, Dai E, Han G, Thakkar K, Dang M, Qin J, Le X, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Song S, Lu Y, Zhang S, Marsden A, Reuben A, Futreal A, Maitra A, Jazaeri A, Cheng X, Ajani J, Swanton C, Abbas H, Gillison M, Bhat K, Green M, Kadara H, Litchfield K, Yee C, Wang L.. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nature Medicine 29(6):1550-1562, 2023.
- Yang J, Chen Y, Jing Y, Green MR, Han L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol 20(4):211-228, 2023. e-Pub 2023. PMID: 36721024.
- Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad LE, Fowler NH, Parmar S, Steiner RE, Hagemeister FB, Nair R, Lee HJ, Rodriguez MA, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin JR. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
- Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR.. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Journal of Clinical Oncology, 2022. PMID: 35952327.
- Han G, Deng Q, Marques-Piubelli M, Dai E, Dang M, Ma M, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie K, Bagaev A, Parra E, Soto L, Parmar S, Hagemeister F, Ahmed S, Iyer S, Samaniego F, Steiner R, Fayad L, Lee H, Fowler F, Flowers C, Strati P, Westin J, Neelapu S, Nastoupil L, Vega F, Wang L, Green M. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discovery, 2022. PMID: 35687817.
- Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
- Jing Y, Liu Y, Li Q, Ye Y, Diao L, Huang Y, Zhou Y, Green MR, Mills GB, Han L. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell 39(12):1558-1559, 2021. e-Pub 2021. PMID: 34678153.
- Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
- Yang H, Green MR. Harnessing lymphoma epigenetics to improve therapies. Blood 136(21):2386-2391, 2020. e-Pub 2020. PMID: 33206943.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
- Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR, Yewdell WT, Raught B, Phillip JM, Jiang Y, Staudt LM, Green MR, Chaudhuri J, Elemento O, Farinha P, Weng AP, Nissen MD, Steidl C, Morin RD, Scott DW, Privé GG, Melnick AM. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell 182(2):297-316.e27, 2020. e-Pub 2020. PMID: 32619424.
- Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov, 2020. e-Pub 2020. PMID: 31915197.
- Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, Cantley LC, Green MR, Lin H, Melnick AM. Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell 35(6):916-931.e9, 2019. PMID: 31185214.
- Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med 11(497), 2019. PMID: 31217338.
- Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discov 8(12):1632-1653, 2018. e-Pub 2018. PMID: 30274972.
- Choi J, Lee K, Ingvarsdottir K, Bonasio R, Saraf A, Florens L, Washburn MP, Tadros S, Green MR, Busino L. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2. Nat Cell Biol 20(May 2018):586-596, 2018. e-Pub 2018. PMID: 29695787.
- García-Ramírez I, Tadros S, González-Herrero I, Martín-Lorenzo A, Rodríguez-Hernández G, Moore D, Ruiz-Roca L, Blanco O, Alonso-López D, Rivas JL, Hartert K, Duval R, Klinkebiel D, Bast M, Vose J, Lunning M, Fu K, Greiner T, Rodrigues-Lima F, Jiménez R, Criado FJG, Cenador MBG, Brindle P, Vicente-Dueñas C, Alizadeh A, Sánchez-García I, Green MR. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood 129(19):2645-2656, 2017. e-Pub 2017. PMID: 28288979.
- Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543(7647):723-727, 2017. e-Pub 2017. PMID: 28329770.
- Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J. Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets. Blood, 2017. e-Pub 2017. PMID: 28801451.
- Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol 2(10):e445-55, 2015. e-Pub 2015. PMID: 26686046.
- Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(24):3679-87, 2015. e-Pub 2015. PMID: 25887775.
- Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453-7, 2015. e-Pub 2015. PMID: 25822800.
- Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, Alizadeh AA. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 112(10):E1116-25, 2015. e-Pub 2015. PMID: 25713363.
- Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun 5:3904, 2014. e-Pub 2014. PMID: 24887457.
- Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121(9):1604-11, 2013. e-Pub 2013. PMID: 23297126.
- Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22(4):547-60, 2012. PMID: 23079663.
- Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611-8, 2012. e-Pub 2012. PMID: 22271878.
- Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117(16):4315-22, 2011. e-Pub 2011. PMID: 21300977.
- Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A 108(7):2873-8, 2011. e-Pub 2011. PMID: 21282644.
- Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268-77, 2010. e-Pub 2010. PMID: 20628145.
Invited Articles
- Green M. Chromatin modifying genes in follicular lymphoma. Blood 131(6):595-604, 2018. PMID: 29158360.
- Lunning M, Green M. Mutation of chromatin modifiers and organizers; an emerging hallmark of B-cell lymphoma. Blood Cancer J 5:e361, 2015.
- Green M, Vicente-Duenas C, Alizadeh A, Sanches Garcia I. Hit-and-run tumor stem cell reprogramming by the Bcl6 oncogene. Cell Cycle 13:1831-1832, 2014. PMID: 24867153.
- Green M, Alizadeh A. Common progenitor cells (CPCs) in mature B-cell malignancies: Implications for therapy. Curr Opin Hematol 21:333-340, 2014. PMID: 24811163.
Patient Reviews
CV information above last modified August 29, 2024